Medpace Holdings, Inc. 4

President & CEO August J. Troendle sold 4,673 shares of Medpace Holdings, Inc. (MEDP) common stock in two open‑market transactions totaling about $2.9 million at roughly $620 per share.

On August 25 and 26, 2026, Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 4,673 shares of Medpace common stock in two open-market transactions executed via a limit order during an open trading window, at weighted average prices of approximately $620 per share. The first sale on August 25, 2026 involved 673 shares at an average price of $620.38, followed by a second sale on August 26, 2026 of 4,000 shares at an average price of $620.03, for aggregate proceeds of roughly $2.9 million. Following these direct sales, Troendle reported direct ownership of 540,544 shares and also disclosed indirect beneficial ownership of an additional 4,733,019 shares held through Medpace Investors, LLC, where he serves as sole manager and controlling unit holder, while disclaiming beneficial ownership beyond his pecuniary interest.

Filing Facts

CIK

1668397

Ticker

MEDP

Form

4

Source Type

fda

Accession

0001622058-26-000008

Alert Tier

7